Market Place
Sourcing Support
Vera Therapeutics Announces Nasdaq-Compliant Inducements
10 Apr 2026 //
GLOBENEWSWIRE
Vera Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
27 Mar 2026 //
GLOBENEWSWIRE
Vera Therapeutics Names Jane Wright-Mitchell Chief Legal Officer
25 Mar 2026 //
GLOBENEWSWIRE
Vera Therapeutics Announces Inducement Grants Under Nasdaq Rules
06 Mar 2026 //
GLOBENEWSWIRE
Vera Therapeutics Issues Inducement Grants Per Nasdaq Lr
06 Feb 2026 //
GLOBENEWSWIRE
Vera Therapeutics Issues Inducement Grants Under Nasdaq LR
09 Jan 2026 //
GLOBENEWSWIRE
Vera Therapeutics Awards Inducements per Nasdaq LR 5635(c)(4)
05 Dec 2025 //
GLOBENEWSWIRE
Vera Therapeutics To Participate At Upcoming Investor Conferences
24 Nov 2025 //
GLOBENEWSWIRE
Vera Therapeutics Inducement Grants Under Nasdaq LR 5635(C)(4)
07 Nov 2025 //
GLOBENEWSWIRE
Vera Therapeutics Inducement Grants Under Nasdaq LR 5635(C)(4)
10 Oct 2025 //
GLOBENEWSWIRE
Vera Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
05 Sep 2025 //
GLOBENEWSWIRE
Vera Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
08 Aug 2025 //
GLOBENEWSWIRE
Vera Therapeutics Grants Inducements Under Nasdaq Listing Rule
10 Jul 2025 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing
09 Jun 2025 //
GLOBENEWSWIRE
Vera`s Shares Surge on Success of Kidney Disease Drug in Trial
02 Jun 2025 //
REUTERS
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing
09 May 2025 //
GLOBENEWSWIRE
Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
09 Apr 2025 //
GLOBENEWSWIRE
Vera Therapeutics Completes Full Enrollment in ORIGIN Ph 3 Trial
03 Apr 2025 //
GLOBENEWSWIRE
Vera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Mar 2025 //
GLOBENEWSWIRE
Vera Therapeutics at TD Cowen 45th Annual Health Care Conf.
27 Feb 2025 //
GLOBENEWSWIRE
Vera Therapeutics Updates Business and Reports Q4 2024 Result
26 Feb 2025 //
GLOBENEWSWIRE
Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
13 Feb 2025 //
GLOBENEWSWIRE
Vera Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
14 Jan 2025 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Rule
22 Nov 2024 //
GLOBENEWSWIRE
Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq
10 Sep 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2024 //
GLOBENEWSWIRE
Vera Therapeutics Appoints David L. Johnson As Chief Operating Officer
01 Jul 2024 //
GLOBENEWSWIRE
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
11 Jun 2024 //
GLOBENEWSWIRE
Vera To Participate At Goldman Healthcare Conference
07 Jun 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
GLOBENEWSWIRE
Vera Therapeutics: FDA Breakthrough Therapy For Atacicept In IgAN
28 May 2024 //
GLOBENEWSWIRE
Vera Therapeutics Q1 2024 Results And Business Update
09 May 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 May 2024 //
GLOBENEWSWIRE
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
11 Apr 2024 //
MORNINGSTAR
Vera Announces Presentations at the 61st European Renal Association Congress
02 Apr 2024 //
GLOBENEWSWIRE
Vera Therapeutics Provides Business Update and Reports 4Q
20 Mar 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Participate at 44th Annual TD Cowen Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Participate in the 6th Annual Biotechnology Conference
02 Feb 2024 //
GLOBENEWSWIRE
Vera Therapeutics Announces Closing of Upsized Public Offering
01 Feb 2024 //
GLOBENEWSWIRE
Vera Announces Pricing of Upsized Public Offering of Class A Common Stock
29 Jan 2024 //
GLOBENEWSWIRE
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
29 Jan 2024 //
PRESS RELEASE
Vera Therapeutics Presents Data Showing eGFR Stabilization in the Phase 2b Trial
25 Jan 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Host In-Person R&D Day in New York
08 Jan 2024 //
GLOBENEWSWIRE
Vera Announces Appointment of Veterans Robert Brenner as CMO
08 Jan 2024 //
GLOBENEWSWIRE
Vera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
27 Dec 2023 //
GLOBENEWSWIRE
Vera Therapeutics Reports Third Quarter Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Vera Presents Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria
04 Nov 2023 //
GLOBENEWSWIRE
Vera Therapeutics Scheduled to Present at November Investor Conferences
30 Oct 2023 //
GLOBENEWSWIRE
Vera Therapeutics to Present Three Posters at the Annual Meeting
13 Oct 2023 //
GLOBENEWSWIRE
Vera Therapeutics Scheduled to Present at September Investor Conferences
31 Aug 2023 //
GLOBENEWSWIRE
Vera Provides Business Update and Reports Second Quarter Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Vera to Participate in 44th Annual Goldman Sachs Global Healthcare Conference
08 Jun 2023 //
GLOBENEWSWIRE
Vera Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Atacicept
07 Jun 2023 //
GLOBENEWSWIRE
Vera Therapeutics Reports First Quarter Financial Results
11 May 2023 //
GLOBENEWSWIRE
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior VP
04 May 2023 //
GLOBENEWSWIRE
Vera Provides Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
27 Feb 2023 //
GLOBENEWSWIRE
Vera Therapeutics Announces Closing of Upsized Public Offering
06 Feb 2023 //
GLOBENEWSWIRE
